We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Adagio Therapeutics Inc (ADGI) USD0.0001

Sell:$25.50 Buy:$37.00 Change: $2.09 (5.85%)
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
Change: $2.09 (5.85%)
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
Change: $2.09 (5.85%)
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Adagio Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The Company's initial focus is on the virus SARS-CoV-2, its variants and the disease caused by this virus, which is known as Coronavirus Infectious Disease (COVID-19). The Company is developing its lead product candidate, ADG20, for the treatment and prevention of coronavirus disease 2019 (COVID-19). ADG20 is designed to be a potent, long-acting and broadly neutralizing antibody for both the treatment and prevention of COVID-19 including disease caused by variants, as either a single or combination agent. The Company is also evaluating broadly neutralizing antibodies, such as ADG10, for potential use in combination with ADG20 for COVID-19.

Contact details

303 Wyman Street, Suite 300
United States
+1 (781) 5303600

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$4.12 billion
Shares in issue:
111.25 million
United States
US dollar

Key personnel

  • Rene Russo
    Chairman of the Board and Co-Founder
  • Tillman Gerngross
    Chief Executive Officer, Co-Founder
  • Laura Walker
    Co-Founder, Chief Scientific Officer
  • Jane Henderson
    Chief Financial Officer
  • Halley Gilbert
    Chief Operating Officer
  • Becky Dabora
    Chief Technology Officer, Chief Marketing Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.